Analysts Set Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Target Price at $38.33

Shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) have earned a consensus rating of “Hold” from the five brokerages that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $38.3333.

Several equities research analysts have recently commented on the stock. Weiss Ratings lowered shares of Pharming Group from a “hold (c-)” rating to a “sell (d)” rating in a report on Monday, May 11th. HC Wainwright reiterated a “buy” rating and set a $37.00 price objective on shares of Pharming Group in a research note on Tuesday, March 24th. Canaccord Genuity Group started coverage on shares of Pharming Group in a report on Friday, April 10th. They set a “buy” rating and a $37.00 price objective on the stock. Wall Street Zen downgraded shares of Pharming Group from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. Finally, Zacks Research upgraded Pharming Group from a “strong sell” rating to a “hold” rating in a report on Friday, April 10th.

Institutional Investors Weigh In On Pharming Group

Hedge funds have recently made changes to their positions in the stock. EverSource Wealth Advisors LLC purchased a new position in Pharming Group in the second quarter valued at about $32,000. NewEdge Advisors LLC raised its holdings in Pharming Group by 11,310.3% in the fourth quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock worth $510,000 after purchasing an additional 28,615 shares in the last quarter. Millennium Management LLC purchased a new stake in shares of Pharming Group during the fourth quarter valued at about $360,000. Finally, SmartHarvest Portfolios LLC purchased a new stake in shares of Pharming Group during the fourth quarter valued at about $224,000. 0.03% of the stock is currently owned by hedge funds and other institutional investors.

Pharming Group Price Performance

Shares of PHAR stock opened at $13.16 on Friday. Pharming Group has a twelve month low of $9.54 and a twelve month high of $21.34. The company has a current ratio of 2.63, a quick ratio of 2.06 and a debt-to-equity ratio of 0.35. The stock has a fifty day simple moving average of $13.13 and a two-hundred day simple moving average of $15.48. The stock has a market capitalization of $931.54 million, a price-to-earnings ratio of 82.26 and a beta of -0.04.

Pharming Group (NASDAQ:PHAR) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.12). Pharming Group had a net margin of 3.30% and a return on equity of 4.64%. The firm had revenue of $72.45 million for the quarter, compared to analysts’ expectations of $92.06 million. On average, analysts predict that Pharming Group will post 0.6 EPS for the current fiscal year.

About Pharming Group

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.